Uninterrupted rivaroxaban vs. uninterrupted vitamin K antagonists for catheter ablation in non-valvular atrial fibrillation Journal Article

Local Library Link: Find It @ Loyola

Authors: Cappato, R.; Marchlinski, F. E.; Hohnloser, S. H.; Naccarelli, G. V.; Xiang, J.; Wilber, D. J.; Ma, C. S.; Hess, S.; Wells, D. S.; Juang, G.; Vijgen, J.; Hugl, B. J.; Balasubramaniam, R.; De Chillou, C.; Davies, D. W.; Fields, L. E.; Natale, A.; VENTURE-AF Investigators
Article Title: Uninterrupted rivaroxaban vs. uninterrupted vitamin K antagonists for catheter ablation in non-valvular atrial fibrillation
Abstract: AIMS: VENTURE-AF is the first prospective randomized trial of uninterrupted rivaroxaban and vitamin K antagonists (VKAs) in patients with non-valvular atrial fibrillation (NVAF) undergoing catheter ablation (CA). METHODS AND RESULTS: Trial size was administratively set at 250, the protocol-specified target. Events were independently and blindly adjudicated. We randomly assigned 248 NVAF patients to uninterrupted rivaroxaban (20 mg once-daily) or to an uninterrupted VKA prior to CA and for 4 weeks afterwards. The primary endpoint was major bleeding events after CA. Secondary endpoints included thromboembolic events (composite of stroke, systemic embolism, myocardial infarction, and vascular death) and other bleeding or procedure-attributable events. Patients were 59.5 +/- 10 years of age, 71% male, 74% paroxysmal AF, and had a CHA2DS2-VASc score of 1.6. The average total heparin dose used to manage activated clotting time (ACT) was slightly higher (13 871 vs. 10 964 units; P 0.001) and the mean ACT level attained slightly lower (302 vs. 332 s; P 0.001) in rivaroxaban and VKA arms, respectively. The incidence of major bleeding was low (0.4%; 1 major bleeding event). Similarly, thromboembolic events were low (0.8%; 1 ischemic stroke and 1 vascular death). All events occurred in the VKA arm and all after CA. The number of any adjudicated events (26 vs. 25), any bleeding events (21 vs. 18), and any other procedure-attributable events (5 vs. 5) were similar. CONCLUSION: In patients undergoing CA for AF, the use of uninterrupted oral rivaroxaban was feasible and event rates were similar to those for uninterrupted VKA therapy. NAME OF THE TRIAL REGISTRY: Clinicaltrials.gov trial registration number is NCT01729871.
Journal Title: European heart journal
ISSN: 1522-9645; 0195-668X
Publisher: . Published by Oxford University Press on behalf of the European Society of Cardiology  
Date Published: 2015
Language: ENG
DOI/URL:

ehv177
Notes: LR: 20150516; CI: (c) The Author 2015; JID: 8006263; OTO: NOTNLM; aheadofprint